.tb-field[data-toolset-blocks-field="203299a22ab9b4467746e3ecd5032d31"] { font-size: 14px; }  h3.tb-heading[data-toolset-blocks-heading="c64a8eae195c288bfd5aec4150db92c6"]  { font-size: 16px; }  .wpv-pagination-nav-links[data-toolset-views-view-pagination-block="cdfd4c4737b2898eba4443dd59a1bf50"] { text-align: left;justify-content: flex-start; } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="ed3832aa6201cbec5b1e5b902dc067e2"] { padding: 25px; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"] { grid-template-columns: minmax(0, 0.665fr) minmax(0, 0.335fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="19e1e13dfc2b82cdc91936dd659e218d"] { background-color: rgba( 243, 241, 241, 1 );border-radius: 3px;padding: 10px;box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 );border: 1px solid rgba( 221, 219, 219, 1 );display: flex; } .tb-field[data-toolset-blocks-field="b4905723ecea41184171014c65948a9a"] { font-size: 12px;line-height: 16px;padding: 0px;margin: 0px; }  .tb-field[data-toolset-blocks-field="c949bea6c10cb48f79d87a6418026524"] { font-size: 12px;line-height: 16px;padding: 0px;margin: 0px; }  .tb-field[data-toolset-blocks-field="f8b4df145ada4a882c0769270c620213"] { font-size: 12px;line-height: 16px;padding: 0px;margin: 0px; }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} @media only screen and (max-width: 781px) {   .tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="19e1e13dfc2b82cdc91936dd659e218d"] { display: flex; }    .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}  } @media only screen and (max-width: 599px) {   .tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="19e1e13dfc2b82cdc91936dd659e218d"] { display: flex; }    .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}  } 

ERT

ERT (www.ert.com) is a leading global provider of high-quality patient safety and efficacy endpoint data collection, cloud analytics and workflow solutions.

ERT delivers a combination of technology, services, and consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process throughout the product lifecycle. By efficiently integrating innovative solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes, and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products. ERT delivers the most widely deployed solutions in: Centralized Cardiac Safety, Respiratory Solutions, Clinical Outcome Assessments (COA) including multi-mode, electronic patient, clinician, and observer reported outcomes solutions (ePRO, eClinRO, eObsRO), Rater Training, Suicidality Risk Assessment, Universal Data Integration, Analytics, and Visualization as well as Scientific & Regulatory Consulting in these areas.

Biopharmaceutical researchers have relied on ERTs products and services for over 40 years, making ERT one of the industrys most trusted eClinical trial solutions providers. In fact, ERTs solutions have been used in over 50% of U.S. FDA approvals for the past three years.

And ERT is continually innovating better health by developing new solutions that help our customers improve the clinical development process. Our state-of-the-art Innovation Lab is dedicated to researching new technologies, tools or ideas that improve clinical data collection and enhance the patients experience during drug development. Through collaboration between ERT scientists, pharmaceutical and technology experts, the Lab is actively exploring new solutions for leveraging wearables and wireless medical devices within clinical trials delivering better patient data to support the development of safe and effective therapies.

ERT is a global organization with headquarters in Philadelphia, PA and offices throughout the U.S., U.K., Switzerland, Japan and Germany.

ERT Enables Clinical Trial Continuity through At-Home Respiratory Solutions

April 1, 2020 - ERT, a global data and technology company that captures critical endpoint data while minimizing uncertainty and risk in clinical trials, today announced multiple options that enable trained healthcare professionals to advance respiratory clinical trials by collecting high-quality spirometry data during patient home visits. ERTís At-Home Respiratory Solutions enable clinical trial sponsors...

ERT Acquires Imaging Solution from Cleveland Clinic

PHILADELPHIA - May 9, 2017 - ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced the acquisition of ImageIQ, originally established as Cleveland Clinicís Biomedical Imaging and Analysis Center. The acquisition enables ERT to offer advanced, end-toend clinical trial imaging analysis using best-in-class technology that delivers compliant...

ERT Executive Recognized for Enhancing Corporate Mission, Values

PHILADELPHIA - March 8, 2017 - ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced that its Chief Financial Officer (CFO), Waqar Nasim has been awarded a SmartCEO Philadelphia Executive Management Award (EMA). The Executive Management Awards program recognizes the leadership and accomplishments of C-suite executives leading...

ERT Clinical Trial Oversight Selected by Premier Research

PHILADELPHIA - Feb 23, 2017-- ERT, a global data and technology company that minimizes risk and uncertainty in clinical trials, today announced that Premier Research, a leading clinical development service provider, has selected ERTís Trial Oversight suite as its trial management solution. Clinical trials are becoming increasingly complex, due in part to an array of...

ERT Recognized for Improving and Accelerating Clinical Research

PHILADELPHIA - Feb 16, 2017-- ERT, a global data and technology company that minimizes risk and uncertainty in clinical trials, today announced it has been named a finalist for the Philadelphia Alliance for Capital and Technologies (PACT) Technology Company of the Year Award. ERT is one of only three companies nominated to receive this recognition....

ERT‚Ä™s eCOA Environment Accelerates Research Without Technology Getting in the Way

PHILADELPHIA - Feb 9, 2017 - ERT, a global data and technology company that minimizes risk and uncertainty in clinical trials, today announced the launch of its refreshed eCOA technology environment, which dramatically simplifies the implementation and management of trials that require collection of Clinical Outcomes Assessments. Designed to support simple to the most complex...

ERT Acquires Exco InTouch

PHILADELPHIA - December 8, 2016 -- ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, today announced the acquisition of Exco InTouch, a leading provider of patient engagement, data capture and digital health solutions. The combined organization will provide the biopharmaceutical industry with the most advanced and comprehensive...

ERT Launches the Industrys First Multi-Language Diagnostic Platform for Respiratory Trials

PHILADELPHIA - December 5, 2016 -- ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, today announced a significant enhancement to MasterScope™, the companyís flagship platform for centralized respiratory clinical trials, making it the industryís first and only multi-language solution. With multi-language capabilities, MasterScope enables sites to manage...

ERT is Pivotal to Health Canada Approval of Rupatadine

PHILADELPHIA - Oct. 19, 2016 -- ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, today announced its support of the regulatory review of Pediapharmís Health Canada approval of rupatadine. ERT conducted the statistical analyses of cardiac safety data collected during the clinical development of rupatadine and developed...